These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8948025)

  • 21. Kinetic analysis of megakaryopoiesis induced by recombinant human interleukin 11 in myelosuppressed mice.
    Saitoh M; Taguchi K; Momose K; Suga K; Ogawa Y; Yasuda S; Miyata K
    Cytokine; 2001 Mar; 13(5):287-94. PubMed ID: 11243707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice.
    Shibuya K; Kuwaki T; Akahori H; Kato T; Miyazaki H
    Leuk Res; 2004 Sep; 28(9):941-6. PubMed ID: 15234571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on growth and differentiation of the HEL cell line.
    Catani L; Gugliotta L; Motta M; Tazzari P; Baravelli S; Tura S
    Haematologica; 1998 May; 83(5):385-91. PubMed ID: 9658720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation.
    Molineux G; Hartley CA; McElroy P; McCrea C; McNiece IK
    Blood; 1996 Aug; 88(4):1509-14. PubMed ID: 8695873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
    Sheridan W; Menchaca D
    Stem Cells; 1998; 16 Suppl 2():193-8. PubMed ID: 11012191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A highly enhanced thrombopoietic activity by monomethoxy polyethylene glycol-modified recombinant human interleukin-6.
    Inoue H; Kadoya T; Kabaya K; Tachibana K; Nishi N; Sato M; Ohsawa M; Mikayama T; Mori KJ
    J Lab Clin Med; 1994 Oct; 124(4):529-36. PubMed ID: 7930877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
    Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
    Fanucchi M; Glaspy J; Crawford J; Garst J; Figlin R; Sheridan W; Menchaca D; Tomita D; Ozer H; Harker L
    N Engl J Med; 1997 Feb; 336(6):404-9. PubMed ID: 9010146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia.
    Farese AM; Hunt P; Grab LB; MacVittie TJ
    J Clin Invest; 1996 May; 97(9):2145-51. PubMed ID: 8621805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on thrombopoietin in preclinical and clinical trials.
    Miyazaki H
    Curr Opin Hematol; 1998 May; 5(3):197-202. PubMed ID: 9664160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells.
    Neelis KJ; Dubbelman YD; Qingliang L; Thomas GR; Eaton DL; Wagemaker G
    Exp Hematol; 1997 Sep; 25(10):1084-93. PubMed ID: 9293906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
    Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
    Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
    Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
    Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mild transient decrease of peripheral red blood cell counts induced by a suprapharmacological dose of pegylated human megakaryocyte growth and development factor in rats.
    Harada K; Ide Y; Tazunoki Y; Imai A; Yanagida M; Kikuchi Y; Imai A; Ishii H; Kawahara J; Izumi H; Kusaka M; Tokiwa T
    J Pharm Pharmacol; 1999 Jul; 51(7):841-6. PubMed ID: 10467960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
    Bennett CL; Evens AM; Andritsos LA; Balasubramanian L; Mai M; Fisher MJ; Kuzel TM; Angelotta C; McKoy JM; Vose JM; Bierman PJ; Kuter DJ; Trifilio SM; Devine SM; Tallman MS
    Br J Haematol; 2006 Dec; 135(5):642-50. PubMed ID: 17054431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
    Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
    Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of the Kasabach-Merritt syndrome with pegylated recombinant human megakaryocyte growth and development factor in mice: elevated platelet counts, prolonged survival, and tumor growth inhibition.
    Verheul HM; Panigrahy D; Flynn E; Pinedo HM; D'Amato RJ
    Pediatr Res; 1999 Nov; 46(5):562-5. PubMed ID: 10541319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF).
    Catani L; Gugliotta L; Campanini E; Mangianti S; Gibellini D; Baravelli S; Vianelli N; Lemoli RM; Tura S
    Br J Haematol; 1998 Jan; 100(1):207-18. PubMed ID: 9450813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marked improvement of thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura by pegylated recombinant human megakaryocyte growth and development factor.
    Shibuya K; Kuwaki T; Tahara E; Yuki C; Akahori H; Kato T; Miyazaki H
    Exp Hematol; 2002 Oct; 30(10):1185-92. PubMed ID: 12384150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.